Delta4 AI

Delta4 AI is a private, preclinical-stage Austrian TechBio company founded in 2018, specializing in AI-driven drug repurposing and indication expansion. Its proprietary Hyper-C platform integrates systems biology, computational modeling, and AI to analyze large-scale biological data, uncovering new therapeutic applications for existing drugs, particularly for rare and complex diseases. The company operates a hybrid business model, offering both platform services to clients and advancing its own internal pipeline of preclinical and clinical programs, primarily focused on kidney diseases, oncology, and Long COVID. Delta4 has gained recognition from Austrian research agencies and partners with platforms like Scientist.com to streamline research collaborations.

Hyper-C, a proprietary AI-powered software platform that integrates systems biology, computational modeling, and large-scale data to understand disease mechanisms and predict new therapeutic uses for existing drugs with known safety profiles.

Delta4 operates in the highly competitive AI-driven drug discovery sector, competing with global players like Exscientia, Recursion, and Insilico Medicine. Its differentiation lies in its specific focus on drug repurposing for rare/complex diseases and its integration of systems biology. Success will depend on demonstrating superior predictive accuracy and successful clinical translation.